• editor.aipublications@gmail.com
  • Track Your Paper
  • Contact Us
  • ISSN: 2456-8015

International Journal Of Medical, Pharmacy And Drug Research(IJMPD)

Assessment Outcomes Dyslipidaemia in Dialysis Patient

Sabah Ali Jaber Alhelu , Thaer Jabbar AL-Zaidy , Ayad Hameed Tailan


International Journal of Medical, Pharmacy and Drug Research(IJMPD), Vol-7,Issue-1, January - February 2023, Pages 19-24 , 10.22161/ijmpd.7.1.3

Download | Downloads : 1 | Total View : 440

Article Info: Received: 17 Jan 2023; Received in revised form: 11 Feb 2023; Accepted: 20 Feb 2023; Available online: 28 Feb 2023

Share

Background: Chronic kidney disease is defined as the presence, for more than three months, of changes in the structure or function of the kidneys, secondary to a progressive decline in the number of nephrons, with a consequent deterioration in health resulting from the inability of the kidneys to perform their excretory functions, softener, and metabolism. Chronic kidney disease (CKD) is a clinical condition caused by the progressive and progressive loss of kidney function. Chronic kidney disease is not only implicated by the gradual deterioration of quality of life and life expectancy when it progresses to more advanced stages but also by the increase in cardiovascular morbidity and mortality, which is the leading cause of death in these patients. Aim: This paper aims to assess the outcomes of dyslipidemia in a dialysis patient. Patients and method: In this study, a descriptive cross-sectional study was applied to study the Assessment Outcomes of Dyslipidemia in Dialysis Patients in Iraq from 4th January 2021 to 7th August 2022. Data were collected for 150 patients in different hospitals in Iraq, where the patients were divided into two groups, the first group of patients, which included DIALYSIS PATIENTS, which included 80, and the second group, the control group, which included patients, which include 70 patients. Results and discussions: collected 150 cases distributed according to dialysis patients (80) and controls (70); the most frequent ages in this study ranged from 40-49 years old 34 (42.5%) patients group, 33 (47.14%) control group with a statistical difference of 0.0831. In this study was evaluated the Outcomes of dyslipidemia in a dialysis patient. Imbalances were found in levels of dyslipidemia which LDL 5.12±3.4 of the patients' group, as for the control group 2.1±3.3-HDL 2.43±2.4 of the patients' group, 1.4±1.5 for the control group, TRIGLYCERIDE 1.75±1.8 of patients group, 0.55±0.43 for the control group with A statistically significant relationship were found between dyslipidemia levels and outcomes in the group of patients at P value < 0.05.

HDL, LDL, CKD, Cirrhosis and Diabetes

[1] Parmar JA, Joshi AG, Chakrabarti M. Dyslipidemia and chronic kidney disease. ISRJ. 2014;3:396–397. [Google Scholar]
[2] Charles RH, Terry AJ. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384. [PubMed] [Google Scholar]
[3] Ahmed MH, Khalil AA. Ezetimibe is a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant. Saudi J Kidney Dis Transplant. 2010;21:1021– 1029. [PubMed] [Google Scholar]
[4] Balode AA, Khan ZH. Serum lipid profile in chronic kidney disease patients on hemodialysis. IJAR. 2013;3:20–22. [Google Scholar]
[5] Burmeister JE, Mosmann CB, Veridiana Borges Costa VB, et al. Prevalence of cardiovascular risk factors in hemodialysis patients – the CORDIAL study. Arq Bras Cardiol. 2014;102:473–480. [PMC free article] [PubMed] [Google Scholar]
[6] Kwan BCH, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein Metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246– 1261. [PubMed] [Google Scholar]
[7] Chen S-C, Hung C-C, Kuo M-C, et al. Association of dyslipidemia with renal outcomes in chronic kidney disease. PLoS One. 2013;8:e55643. [PMC free article] [PubMed] [Google Scholar]
[8] Wanner C, Ritz E. Reducing lipids for CV protection in CKD patients—current evidence. Kidney Int. 2008;74:24–28. [PubMed] [Google Scholar]
[9] Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011;5:41–48. [PMC free article] [PubMed] [Google Scholar]
[10] Molitch ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1090–1099. [PubMed] [Google Scholar]
[11] Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, Yoshida H. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int. 2003;64:1829–1837. [PubMed] [Google Scholar]
[12] Kronenberg F, Lingenhel A, Neyer U, et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl. 2003;84:113–116. [PubMed] [Google Scholar]
[13] Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887– 1893. [PubMed] [Google Scholar]
[14] Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–459. [PubMed] [Google Scholar]
[15] Mikolašević I, Lukenda V, Sladoje-Martinović B, et al. Metabolic complications after solid organ transplantation. Medicina Fluminensis. 2014;50:61–66. [Google Scholar]
[16] Kahwaji JM, Dudek RR. How can we manage hyperlipidemia and avoid rhabdomyolysis in transplant patients? Perm J. 2006;10:26–28. [PMC free article] [PubMed] [Google Scholar]
[17] Mesquita J, Varela A, Medina JL. Dyslipidemia in renal disease: causes, consequences, and treatment. Endocrinol Nutr. 2010;57:440–448. [PubMed] [Google Scholar]
[18] Thompson M, Ray U, Yu R. Kidney function as a determinant of HDL and triglyceride concentrations in the Australian population. J Clin Med. 2016;5:35. [PMC free article] [PubMed] [Google Scholar]
[19] Omran J, Al-Dadah A, Dellsperger KC. Dyslipidemia in patients with chronic and end-stage kidney disease. Cardiorenal Med. 2013;3:165–177. [PMC free article] [PubMed] [Google Scholar]
[20] Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:259–305. [Google Scholar]
[21] Türk TR, Voropaeva E, Kohnle M, et al. Ezetimibe treatment in hypercholesterolaemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant. 2008;23:369–373. [PubMed] [Google Scholar]